Multisystem Inflammatory Syndrome in Children
A severe, delayed inflammatory reaction in children weeks after a COVID-19 infection, causing high fever, rash, and potentially dangerous heart problems.
Emergency Management: Cardiogenic or vasodilatory shock requires rapid transport to a Pediatric ICU, fluid resuscitation (cautiously, due to poor heart function), and initiation of inotropes/vasopressors (e.g., Epinephrine, Milrinone).
Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but severe post-infectious hyperinflammatory condition occurring 2 to 6 weeks after infection with SARS-CoV-2. It is characterized by persistent fever, profound systemic inflammation, and multi-organ dysfunction, most notably affecting the cardiovascular and gastrointestinal systems.
Detailed Overview
MIS-C shares clinical features with Kawasaki disease, Toxic Shock Syndrome, and Macrophage Activation Syndrome. Unlike acute COVID-19, which is usually mild in children, MIS-C is a delayed immune dysregulation phenomenon. It leads to intense cytokine release, causing vasoplegia, myocardial dysfunction, and sometimes coronary artery aneurysms. Early recognition is vital, as rapid progression to cardiogenic or vasodilatory shock occurs in a significant percentage of patients, necessitating intensive care support and immunomodulatory therapy.
Epidemiology & Demographics
Rare complication of SARS-CoV-2 (incidence estimated at 1 in 3,000-4,000 pediatric infections). Median age is 8-9 years. Black and Hispanic children are disproportionately affected.
Etiological Mechanism
A delayed, dysregulated immune response to SARS-CoV-2 (the virus causing COVID-19).
Primary Causes
["Prior exposure or infection with SARS-CoV-2."]
While the exact mechanism remains under investigation, it is believed to be driven by autoantibodies, immune complex deposition, or a viral superantigen effect that triggers robust activation of macrophages and T cells. This results in a 'cytokine storm' (massive release of IL-1, IL-6, TNF-alpha). The intense inflammation causes endothelial damage, increasing vascular permeability (leading to shock and edema) and causing direct myocardial depression and potential coronary artery arteritis.
Diagnostic Criteria & Guidelines
CDC criteria: 1) Age < 21 years. 2) Fever (>38.0°C for ≥24 hours). 3) Lab evidence of inflammation. 4) Severe illness requiring hospitalization with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, GI, dermatologic or neurological). 5) No alternative plausible diagnoses. 6) Positive for current/recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to onset.
Intravenous Immunoglobulin (IVIG) 2 g/kg as a single dose over 10-12 hours, AND systemic glucocorticoids (Methylprednisolone 1-2 mg/kg/day IV). Plus prophylactic low-dose aspirin (3-5 mg/kg/day) to prevent coronary thrombosis.
Second-Line & Adjunctive Therapy
For refractory disease or severe shock: High-dose pulse Methylprednisolone (10-30 mg/kg/day for 3 days), followed by biologic agents such as Anakinra (IL-1 receptor antagonist, 2-10 mg/kg/day SQ/IV) or Infliximab (TNF inhibitor).
Surgical & Procedural Management
None specific for the disease; ECMO (Extracorporeal Membrane Oxygenation) may be required for refractory cardiogenic shock.
Patient Counseling & Advice
Counsel parents that while the illness is critical, the vast majority of children recover normal heart function within weeks to months with treatment. Emphasize the need for strict cardiology follow-up.
Follow-Up & Monitoring Schedule
Repeat echocardiogram and ECG at 1-2 weeks, 4-6 weeks, and 1 year after discharge to monitor coronary arteries and myocardial function.
Preventive Strategies
COVID-19 vaccination is highly effective at preventing MIS-C in children.
Favorable with prompt treatment. Mortality is low (1-2%). Most patients regain normal left ventricular function and coronary dilations often regress, though long-term outcomes of coronary changes are still being studied.